GH Research PLC
GHRS evidence brief
What we can confirm
- Market Cap:
- $1.89B
- Next Catalyst:
- Phase3_Start · Oct 14, 2026
What it means
What to watch
Prepared research question
What matters most for GHRS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GHRS
GH Research PLC (GHRS) is a clinical-stage biopharmaceutical company developing novel mebufotenin (5-MeO-DMT) therapies for psychiatric and neurological disorders, with a primary focus on its inhalable product candidate GH001.
Key risk: No approved products or revenue
Financial data as of Dec 31, 2025.
Tracking 1238 clinical trials · 19 catalysts for GH Research PLC.
GH Research PLC (GHRS) is a clinical-stage biopharmaceutical company developing novel mebufotenin (5-MeO-DMT) therapies for psychiatric and neurological disorders, with a primary focus on its inhalable product candidate GH001.
- GH Research PLC is developing three mebufotenin product candidates: GH001 (inhalable), GH002 (injectable), and GH003 (intranasal), targeting psychiatric and neurological disorders [sec · filed 2023-06-02].
- As of December 31, 2025, the company reported cash and equivalents of $246.3 million [sec].
- The company has completed Phase 1 and Phase 1/2 clinical trials for GH001, but only in the Netherlands, and has not yet initiated pivotal trials or obtained marketing approval for any product candidate [sec · filed 2023-06-02].
- GH Research expects to incur significant losses for the foreseeable future, with expenses anticipated to increase as it expands clinical development and manufacturing activities [sec · filed 2023-06-02].
- The company's strategy centers on advancing GH001, GH002, and GH003 through clinical trials, with a focus on ultra-rapid and durable remissions in psychiatric and neurological disorders [sec · filed 2023-06-02].
What works
- The company has a substantial cash position of $246.3 million as of December 31, 2025, which may provide a multi-year runway to fund ongoing R&D and clinical programs [sec].
- GH Research has a focused pipeline of three proprietary mebufotenin product candidates (GH001, GH002, GH003) targeting large therapeutic areas in psychiatric and neurological disorders [sec · filed 2023-06-02].
- The company has completed initial Phase 1 and Phase 1/2 clinical trials for its lead candidate GH001, demonstrating early-stage clinical execution capability [sec · filed 2023-06-02].
What to weigh
- GH Research has not yet initiated or completed a pivotal clinical trial, obtained marketing approval, or generated any meaningful revenue from product sales [sec · filed 2023-06-02].
- The company expects to incur significant and increasing losses for the foreseeable future as it expands clinical trials and manufacturing, with no guarantee of achieving profitability [sec · filed 2023-06-02].
- All completed clinical trials to date have been conducted only in the Netherlands, and the company has no experience with U.S. regulatory processes or commercial-scale manufacturing [sec · filed 2023-06-02].
- The company faces risks common to early-stage biotech firms, including dependence on key individuals, competition from larger and better-capitalized companies, and the need for additional financing [sec · filed 2023-06-02].
From the filings
Quoted directly from source documents.
GH Research's lead product candidate is GH001, an inhalable mebufotenin therapy.
“Advancing GH001, our inhalable mebufotenin product candidate,”
SEC filings · June 2, 2023
The company has not yet obtained marketing approval for any product candidate.
“obtained marketing approval for any product candidates, manufactured a commercial scale product or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization.”
SEC filings · June 2, 2023
GH Research expects to incur significant losses for the foreseeable future.
“to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates”
SEC filings · June 2, 2023
Catalyst timeline
- 2026-10-14 · Phase3_Start — Veterans' Intervention Blending NeuRomodulation and YogA for Chronic Low Back PaiN Treatment: VIBRANT — Initiation of a Phase 3 trial for a novel intervention combining neuromodulation and yoga for chronic low back pain in veterans.
- 2026-10-15 · Phase3_Start — Safety and Efficacy of Ivarmacitinib Versus Glucocorticoids in Patients With Mild-to-Moderate Systemic Lupus Erythematosus — Start of a Phase 3 noninferiority trial comparing ivarmacitinib to glucocorticoids for systemic lupus erythematosus.
- 2026-10-15 · Phase3_Start — A Phase 3, Single-Arm, Open-Label, Long-Term Extension Study of Enpatoran in Active Cutaneous Lupus [Elowen-LTE] — Long-term safety and efficacy extension study for enpatoran in cutaneous lupus patients.
- 2026-10-29 · Phase2_Start — Phase 2b Trial of JNJ-95597528 for Moderate to Severe Asthma — Dose-ranging Phase 2b trial evaluating JNJ-95597528 in adults with inadequately controlled asthma.
- 2026-10-31 · Phase2_Start — Pilot Trial of Subcutaneous Semaglutide in Acute Ischaemic Stroke — Pilot randomized trial assessing semaglutide in stroke patients treated with endovascular thrombectomy.
- 2026-11-01 · Phase1_Start — Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders — Phase 1 study on stem cell mobilization and apheresis for blood disorders.
- 2026-11-02 · Phase3_Start — Integrative Digital Treatment for Chronic Pain and Addiction in Veterans with Opioid Use Disorder — Phase 3 trial of an integrative digital treatment for chronic pain and opioid use disorder in veterans.
- 2026-12-01 · Phase2_Start — Tranexamic Acid in Total Ankle Replacement Wound Complications — Pilot randomized trial evaluating tranexamic acid for wound complications in total ankle replacement.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — GH Research has no marketed products, no revenue from product sales, and has not completed any pivotal trials [sec · filed 2023-06-02].
- Increasing losses and cash burn — The company expects losses to increase as it expands R&D and clinical activities, with no guarantee of profitability [sec · filed 2023-06-02].
- Limited clinical and regulatory experience — All completed trials are in the Netherlands; no U.S. regulatory submissions or commercial manufacturing experience [sec · filed 2023-06-02].
- Dependence on key individuals and financing — The company relies on key personnel and may need additional financing to sustain operations beyond current cash runway [sec · filed 2023-06-02].
What to watch
- Initiation and progress of Phase 3 trials for GH001 and other candidates, including the VIBRANT trial for chronic low back pain starting October 2026 [catalyst].
- Expansion of clinical trials into the United States and other geographies, as flagged in the company's strategy [sec · filed 2023-06-02].
- Cash runway and burn rate updates, given the company's $246.3M cash position as of December 2025 and expected increasing losses [sec].
- Any regulatory milestones or partnership announcements that could provide non-dilutive funding or validation [sec · filed 2023-06-02].
Sources: Catalysts · SEC filings · Generated October 11, 2026 · How we verify sources →
Run GH Research PLC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GH Research PLC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
54
Total value held
$668.5M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 10,763,288 | $151.3M |
| bvf inc/il | 8,650,158 | $121.6M |
| ra capital management, l.p. | 7,676,697 | $107.9M |
| rtw investments, lp | 5,933,815 | $83.4M |
| fmr llc | 5,136,045 | $72.2M |
| avoro capital advisors llc | 1,800,000 | $25.3M |
| toronto dominion bank | 1,397,873 | $19.7M |
| troluce capital advisors llc | 990,472 | $13.9M |
| millennium management llc | 937,898 | $13.2M |
| jefferies financial group inc. | 712,300 | $10.0M |
Showing top 10 of 54 institutional holders of GH Research PLC. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 10.6%
- Days to cover
- 14.8
- Shares short
- 2,150,354
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GHRS short interestFrequently asked questions
What is the AI investment thesis for GH Research PLC?
GH Research PLC (GHRS) is a clinical-stage biopharmaceutical company developing novel mebufotenin (5-MeO-DMT) therapies for psychiatric and neurological disorders, with a primary focus on its inhalable product candidate GH001.
What is GH Research PLC's next catalyst?
GH Research PLC's next tracked catalyst is a Phase3_Start event — "Phase3_Start: Veterans' Intervention Blending NeuRomodulation and YogA for Chronic Low Back PaiN Treatment: VIBRANT" — expected October 14, 2026.
Who is the CEO of GH Research PLC?
Dr. Velichka Valcheva M.D., M.Sc. is the chief executive officer of GH Research PLC (GHRS).
Where is GH Research PLC headquartered?
GH Research PLC (GHRS) is headquartered in Dublin, Ireland.
What therapeutic areas does GH Research PLC focus on?
GH Research PLC develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Hematology, Nephrology, Musculoskeletal, Gastroenterology, Endocrinology, Reproductive, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.